To address the demands of a growing population and enhance food and nutrition security, a transition from traditional chemical-derived production is essential. Biomanufacturing, known for its efficient use of natural resources, offers an ideal solution. Acies Bio recently added fermentation capacity and more versatile equipment for downstream processing and formulation.
This scrappy young city in the heart of Europe is rapidly becoming a magnet for successful start-ups and companies looking for plenty of room to grow, as well as a culture of cooperation and trust.
Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Ikxinta, a life sciences advisory firm that originated in the Basque Country in 2018, collaborates with scientists, industry innovators, and investors to propel clients in scientific frontiers
Manufacturing of COVID vaccines showed that large-scale production of lipid nanoparticles (LNPs) as a delivery vehicle for mRNA vaccines is already possible. As nanocarrier-based formulations became mainstream, however, insufficiencies in existing technologies for routine GMP manufacturing became apparent. LEON is committed to bridging these technology gaps through its unique FR-JET technology and innovative manufacturing equipment.
Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.
For 25 years now, BioM has been the network organisation of the biotechnology sector in Munich and Bavaria. To shape the future of biotechnology, BioM identifies relevant and sustainable local, regional and global trends and creates a unique ecosystem for innovation and growth.
Individually customised therapies for every patient this is the vision of the future which numerous companies, research institutions, and clusters focusing on precision medicine in Saxony are working along the entire value creation chain. They are primarily active in oncology and have gained national and international acclaim and renown both in highly specialised cancer diagnostics and innovative treatment methods.
Austria has gained an outstanding reputation as a research location in the field of life sciences both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem
CAR-T therapies represent a new successful strategy for the treatment of hematological malignancies; however, recent studies have revealed some limitations, including the occurrence of graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndromes (CRS). This has prompted researchers to look for alternative, safer cells, such as natural killer (NK) cells 1. NK cells are lymphocytes that kill tumor cells and virus-infected cells non-specifically, without prior sensitization. CAR-NK therapy involves the modification of NK cells with mature chimeric antigen receptor (CAR) technology to exploit their unique target cell recognition mechanism and broad tumor-killing ability. Figure 1 illustrates the CAR-NK therapeutic strategy 1. Compared with CAR-T therapy, CAR-NK therapy has numerous advantages, such as lower GVHD and significantly reduced CRS toxicity and immune effector cell-associated neurotoxicity syndrome toxicity, which enhance overall safety 2, 3. In addition, NK cells have multiple tumor recognition sites, thus potentially reducing antigenic escape failure 4.